78 results about "CD163" patented technology

Methods for treating a patient having a solid tumor are disclosed, comprising: (a) obtaining a tumor sample from the patient; (b) assessing the sample for levels of biomarkers for at least one of innate immune cells and adaptive immune cells; and (c) administering an effective amount of an immunotherapy to the patient if the sample comprises elevated levels of CD68+ PD-L1+ macrophages and CD8+ T cells compared to control and / or elevated levels of CD20+ B cells compared to control and / or low levels of CD163 expression compared to control and PD-L1 expression of greater or equal to (≥) 50%.

The present invention relates to improved antibodies targeting CD163. In particular, the present invention relates to improved antibodies targeting CD163 with improved capabilities in relation to inducing Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).

Disclosed are methods for treating a patient having a solid tumor, the methods comprising: (a) obtaining a tumor sample from the patient; (b) evaluating the sample for the level of a biomarker for at least one of innate and adaptive immune cells; and (c) administering to the patient an effective amount of immunotherapy if the sample contains elevated levels of CD68+PD-L1+ macrophages and CD8+ T cells relative to a control and / or elevated levels of CD20+ B cells relative to a control and / or low levels of CD163 expression and 50% or greater (≧) PD-L1 expression relative to a control.

The application belongs to the technical field of biotechnology, and particularly relates to a marker for prognosis evaluation of acute myeloid leukemia and application thereof, wherein the marker is HCK-positive mono-like cells, the HCK-positive mono-like cells are determined by co-positivity of antigens CD163, antigen CD68, antigen FCN1 and antigen HCK, and the application provides a marker with high sensitivity, strong specificity and good universality, which is used for detecting adult acute myeloid leukemia bone marrow or peripheral blood samples, so as to assist in judging the clinical prognosis of patients with acute myeloid leukemia.

The invention belongs to the technical field of biology, and discloses a BHK-21 cell line, the BHK-21 cell line can express porcine CD163 protein, the cell line is high in hereditary stability and high in PRRSV sensitivity, can be used in virus proliferation, vaccine production and basic experiments, and can provide a new tool for PRRSV vaccine production and mandatory research. Meanwhile, the invention also discloses a preparation method and application of the cell line.

The invention relates to molecular biology and biomedicine technologies, and aims to provide a preparation method and application of an efficient targeting swine fever nano vaccine. The invention provides an APC cell targeted hog cholera virus self-assembled protein nanoparticle, which is obtained by carrying out fusion connection expression on a recombinant plasmid of an APC cell targeted nanoparticle mi3-PTC with a sequence as shown in SEQ ID NO.3 and a hog cholera virus antigen with a sequence as shown in SEQ ID NO.5-12, and further mixing with pharmaceutically acceptable auxiliary materials to prepare a vaccine product for preventing and / or treating hog cholera virus infection. The APC cell targeting polypeptide can be displayed on the surface of the nanoparticle mi3, and the nanoparticle is directionally carried to the APC cell expressing CD163, so that the internalization, storage and distribution capabilities of the nanoparticle are remarkably improved in vivo and in vitro, and the vaccine can remarkably improve the immune response to the swine fever antigen.

The present application relates to a porcine reproductive and respiratory syndrome virus infectious clone construction and rescue method, and belongs to the technical field of bioengineering. The porcine reproductive and respiratory syndrome virus infectious clone contains a full genome sequence of the porcine reproductive and respiratory syndrome virus, and the nucleotide sequence of the full genome sequence is the 26th to 15384th nucleotide of SEQ ID NO: 1 or a fragment having more than 80% identity with SEQ ID NO: 1 and having the same function. The present application also provides a plasmid pCAGGS-HA-CD163 expressing a porcine CD163 gene. By co-transfecting the aforementioned two plasmids into HEK-293T cells, the virus is rescued in vitro, a first porcine reproductive and respiratory syndrome virus infectious clone rescue platform based on HEK-293T cells is successfully built, and the porcine reproductive and respiratory syndrome virus is successfully rescued.

The invention discloses a screening method and application of idiopathic pulmonary fibrosis related molecular targets, and belongs to the technical field of biological medicines.The screening method comprises the steps that firstly, distribution deviation of mRNA in transcriptome sequencing data in different samples is evaluated through TPM; and analyzing the metabolic data through PCA. Then, Mfuzz analysis is carried out, expression trends of the genes and metabolites are researched, clustering is carried out according to different expression trends, and the genes and metabolites with trend specificity are recognized. In addition, four control groups are subjected to differential expression analysis, and then enrichment analysis is performed. The differentially expressed genes are then intersected with trend-specific genes to determine potential candidate genes and metabolites. Through correlation analysis of the candidate metabolites, correlation coefficients of 18 hub genes and 5 key metabolites are identified to be greater than 0.85. The other two key genes (Cd163 and Per3) are found by crossing the differentially expressed genes with the identified key genes by using a GEO IPF database.

The invention discloses a method for preparing a CD163 gene editing pig based on a CRISPR (clustered regularly interspaced short palindromic repeats) / Gs12-7MAX system. The method specifically comprises two editing strategies: one is to edit a sixth intron and a seventh intron of a CD163 gene to realize accurate deletion of a seventh exon so as to obtain a porcine fibroblast monoclonal cell with homozygous deletion of the seventh exon; and 2, editing aiming at a seventh exon of the CD163 gene, and inducing the exon to generate frame-shift mutation to obtain a gene editing pig. The technical system established by the invention has the advantages of high editing efficiency, strong accuracy and simplified operation process, provides a new effective strategy for prevention and control of PRRSV (porcine reproductive and respiratory syndrome), and has important popularization and application values in creation of new materials for pig disease-resistant breeding.

The present disclosure relates to methods of creating Porcine Reproductive and Respiratory Syndrome virus (PRRSv) resistant pigs by gene silencing. In particular, the methods comprise using tools such as CRISPR / CAS9 to edit genes that either directly encode or encode molecules that are processed into non-coding RNA molecules to induce or modify their silencing activity against CD163 and / or in cells of pigs for the purpose of promoting PRRSv resistance.

The present disclosure provides a vaccine comprising a modified live PRRS-1 virus attenuated in a cell expressing porcine CD163 for inducing protective immunity in a piglet of 60 hours old or more wherein the vaccine is intranasally administered to the piglet.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

The invention discloses an antibody combination suitable for detecting DLBCL immune microenvironment by an imaging mass spectrometer, a kit and application. The antibody combination is an antibody for resisting alpha SMA, an antibody for resisting HLADR, an antibody for resisting CD20, an antibody for resisting CD56, an antibody for resisting Vimentin, an antibody for resisting CD8a, an antibody for resisting CCL17, an antibody for resisting CCR6, an antibody for resisting IL3CD123, an antibody for resisting CXCL12, an antibody for resisting BCL2, an antibody for resisting PD1, an antibody for resisting CD163, an antibody for resisting CD45RO, an antibody for resisting ICOS, an antibody for resisting GranzymeB, an antibody for resisting CXCR5, an antibody for resisting Ki67, an antibody for resisting PDL1, an antibody for resisting Bcl6, an antibody for resisting CD31, an antibody for resisting CD163, an antibody for resisting CD45RO, an antibody for resisting CD27, an And all the antibodies are marked. The DLBCL immune microenvironment can be more comprehensively and efficiently identified by using the antibody combination disclosed by the invention.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

Provided herein are, inter alia, multispecific proteins that are, e.g., capable of simultaneously binding EpCAM (e.g., hEpCAM) and CD163 (e.g., hCD163) expressed on the surface of the same cell; nucleic acid molecules encoding the same; and cells expressing the same. The disclosure further relates to pharmaceutical composition comprising the same; and methods of utilizing the same, including, e.g., methods of treating cancer.

The invention discloses an application of a CQ0343 compound in a medicine for treating PRRS (porcine reproductive and respiratory syndrome), and cell experiments prove that the compound CQ0343 can be effectively combined with a CD163 receptor so as to block an infection pathway of PRRSV (porcine reproductive and respiratory syndrome virus) and effectively inhibit an infection process of the PRRSV; meanwhile, qPCR (quantitative polymerase chain reaction) verifies that the CQ0343 compound can effectively inhibit the replication of PRRSV (porcine reproductive and respiratory syndrome virus), and the CQ0343 compound shows a good PRRSV resisting effect by integrating the results.

To provide pigs that exhibit resistance to porcine reproductive respiratory syndrome virus (PRRSV). [Solution] This disclosure relates to a genetically modified pig in which at least one allele of the SIGLEC-1 gene is inactivated and / or at least one allele of the CD163 gene is inactivated. A genetically modified pig in which both alleles of the SIGLEC-1 gene and / or both alleles of the CD163 gene are inactivated is resistant to porcine reproductive respiratory syndrome virus (PRRSV). Methods for producing such transgenic pigs are also provided.

The invention relates to the technical field of biology, and discloses a kit for predicting clinical pregnancy outcome of first-time frozen embryo transplantation. The kit comprises immune cells and immune factors in blood, the immune cells comprise CD19 < + > B cells, CD3 < + > T cells, CD4 < + > Th cells, CD8 < + > Ts cells, CD4 < + > / CD8 < + > ratio cells, CD56 < + > NK cells, CD68 < + > monocytes, CD86 < + > M1 sample monocytes, D206 < + > M2 sample monocytes and CD163 < + > M2 sample monocytes; the immune factors comprise IL-1beta, IL-2r, IL-6, IL-8 and TNF (Tumor Necrosis Factor)-alpha. According to the application, the importance of the peripheral blood CD163 + M2 sample mononuclear cell on predicting the continuous pregnancy of first embryo implantation of an FE T patient is confirmed, and the peripheral blood CD163 + M2 sample mononuclear cell is prompted to be possibly a biomarker of an FET period.

The invention relates to the technical field of biological medicine and tissue engineering, in particular to a tissue engineering blood vessel and a preparation method and application thereof. The tissue engineering blood vessel is obtained by modifying interleukin 24 (IL-24) on the surface of an acellular blood vessel, after the tissue engineering blood vessel is transplanted into a body, the number of CD31 + and CD34 + cells can be remarkably increased, and infiltration of M2 type macrophages (CD163 +) on the surface of the blood vessel is remarkably increased; the expression of HIF-1 alpha (hypoxia marker) and MMP9 is obviously reduced; the expression of the nerve specific protein S-100 is obviously increased, thrombosis and intimal hyperplasia are effectively inhibited, and the patency rate of transplanted blood vessels is obviously increased.

The invention discloses a serum protein combination marker for monitoring liver fibrosis reversion of chronic hepatitis B patients after long-term treatment and application thereof. The invention first discloses a serum protein combination marker for monitoring liver fibrosis reversion of chronic hepatitis B patients after long-term antiviral treatment, and the serum protein combination marker comprises SERPINA7, CD163 and CFHR4. The invention further discloses application of the marker in preparation of products for monitoring liver fibrosis reversion of chronic hepatitis B patients after long-term treatment. By detecting the content ratio of the serum protein combination marker before and after long-term antiviral treatment of chronic hepatitis B patients, the liver fibrosis reversion state can be accurately monitored, and the performance is obviously superior to that of instantaneous elastography and conventional noninvasive indexes. In addition, the serum protein combined marker is based on blood detection, is noninvasive and convenient, and can provide a reliable basis for treatment effect evaluation and clinical decision.

The invention provides a monoclonal antibody for detecting pig source CD163 protein and a corresponding antigen epitope peptide. Wherein the hybridoma cell strain used for preparing the monoclonal antibody is CCTCC (China Center For Type Culture Collection) NO: C2025258. The monoclonal antibody provided by the invention is good in specificity, has good affinity with pCD163, and is clear in epitope information. The antibody can significantly inhibit the infection efficiency of PRRSV pedigree strains in alveolar macrophages, has a good PRRSV in-vitro blocking effect, can be used for developing a high-specificity pCD163 detection reagent, and is expected to be used as a candidate drug for passive immune prevention and treatment of PRRS.

The invention discloses a method for constructing MSTN (myostatin) gene knockout porcine primary cells, which comprises the following steps: designing and constructing plasmids capable of efficiently knocking out MSTN genes by utilizing an efficient and simple gene modification technology TALEN (transcription activator-like effector nodules) technology; a gene editing target site is designed for a pig MSTN gene, the target site can be specifically recognized by Cas9 endonuclease, so that double-strand breakage is mediated, the gene is mutated in a non-homologous end connection mode under the action of a self-repairing system, then an sgRNA composition is designed, tRNA-sgRNA-sgRNA scaffold is used as a minimum repetitive unit, and the target site is specifically recognized by Cas9 endonuclease. The Cas9-CD163-MSTN polycistron vector is constructed by using a PTG / Cas9 strategy, so that the target MSTN gene is efficiently and accurately knocked out, and therefore, the Cas9-CD163-MSTN polycistron vector has a relatively good application prospect in pig germplasm improvement.

The present disclosure relates to methods and compositions useful for prevention of porcine reproductive and respiratory syndrome virus (PRRSv) in animals, including animals of the species Sus scrofa. The present teachings relate to swine wherein at least one allele of a CD163 gene has been inactivated, and to specific methods and nucleic acid sequences used in gene editing to inactivate the CD163 gene. Swine wherein both alleles of the CD163 gene are inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSv). Elite lines comprising homozygous CD163-edited genes retain their superior properties.

A pharmaceutical composition comprising HLA-A2-expressing mesenchymal stem cells as an effective ingredient and its use in prevention or treatment of inflammatory disease are disclosed. The mesenchymal stem cells expressing HLA-A2 on the surface thereof inhibit the secretion of the inflammatory cytokine TNF-a and increase the expression of the anti-inflammatory markers CD163 and Arg-1, so that the pharmaceutical composition comprising the mesenchymal stem cells as an effective ingredient can be advantageously used for suppressing inflammation or treating inflammatory diseases.

The present disclosure provides a monoclonal antibody that binds to porcine CD163 for use in the treatment or prevention of porcine reproductive and respiratory syndrome (PRRS) virus infection in a pig. Preferred antibodies comprise an antigen binding domain that binds to porcine CD163, the antigen binding domain comprising at least one heavy chain variable region comprising three complementarity determining regions (CDRs), wherein the heavy chain variable region comprises a variable heavy chain (VH) CDR2 comprising the amino acid sequence XYAD or XYAE or XYAN, wherein X can be any amino acid. Also provided are nucleic acid molecules, expression vectors, and compositions.

The invention belongs to the technical field of biology, and particularly relates to a marker for prognosis evaluation of acute myelogenous leukemia and application of the marker, the marker is HCK-positive mono-like cells, and the HCK-positive mono-like cells are determined when an antigen CD163, an antigen CD68, an antigen FCN1 and an antigen HCK are co-positive. The kit is used for detecting bone marrow or peripheral blood samples of adult acute myelogenous leukemia so as to assist in judging clinical prognosis conditions of patients with acute myelogenous leukemia.

The present disclosure provides compositions and methods for decreasing permissiveness to infection by PRRSV. The methods involve inserting peptides or oligopeptides into the CD163 SRCR domain 5 to disrupt the protein structure and thereby prevent PRRSV infection. The deletion of the exon 13 region of PSTII eliminates infection. The replacement of cysteine residues with alanines in SRCR5 as a means to disrupt disulfide bond formation. The final method is the deletion of, or amino acid substitution within the SRCR4-5 interdomain region.

The present disclosure relates methods and compositions useful for prevention of porcine reproductive and respiratory syndrome virus (PRRSv) in animals, including animals of the species Sus scrofa. The present teachings relate to swine wherein at least one allele of a CD163 gene has been inactivated, and to specific methods and nucleic acid sequences used in gene editing to inactivate the CD163 gene. Swine wherein both alleles of the CD163 gene are inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSv). Elite lines comprising homozygous CD163 edited genes retain their superior properties.

This invention relates to improved antibodies targeting CD163. In particular, this invention relates to improved antibodies targeting CD163 with improved capabilities associated with inducing antibody-dependent cell-mediated cytotoxicity (ADCC).

The present disclosure relates to methods and compositions useful for prevention of porcine reproductive and respiratory syndrome virus (PRRSv) in animals, including animals of the species Sus scrofa. The present teachings relate to swine wherein at least one allele of a CD163 gene has been inactivated, and to specific methods and nucleic acid sequences used in gene editing to inactivate the CD163 gene. Swine wherein both alleles of the CD163 gene are inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSv). Elite lines comprising homozygous CD163-edited genes retain their superior properties.